Iovance Biotherapeutics, Inc.
IOVAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Iovance Biotherapeutics, Inc. (IOVA) is listed under Biotechnology. At a $3.94B market cap, Iovance Biotherapeutics, Inc. ranks as a mid-cap company within healthcare. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma.
Market Cap
$3.94B
Beta
0.83
P/E (TTM)
—
P/E (Fwd)
-30.28
EPS (TTM)
$-0.69
EPS (Fwd)
$-0.29
ROE
-40.4%
ROA
-20.3%
Cash
$297.7M
Total Debt
$46.0M
Free CF
-$187.8M
52W Change
269.3%
Annual Financials
Cash vs Debt
Where IOVA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, IOVA finished 99.08% above its 150-day moving average ($4.33) and 122.74% above its 200-day moving average ($3.87). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IOVA overbought or oversold?
At the September 3, 2026 close, IOVA's RSI(14) was 69.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $297.7M in cash comfortably exceeding the $46.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$187.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -40.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Iovance Biotherapeutics, Inc.'s trajectory.